Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant TNFSF11 (Denosumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200656
  • Target See all TNFSF11 (Denosumab Biosimilar) products
    TNFSF11 (Denosumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    • 1
    Mouse
    Clonality
    • 2
    Monoclonal
    Conjugate
    • 2
    This TNFSF11 (Denosumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Denosumab Biosimilar, Human RANKL Monoclonal Antibody
    Specificity
    The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
    Characteristics
    Recombinant Humanized IgG2 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
    Isotype
    IgG2 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    TNFSF11 (Denosumab Biosimilar)
    Abstract
    TNFSF11 (Denosumab Biosimilar) Products
    Synonyms
    CD254 antibody, ODF antibody, OPGL antibody, OPTB2 antibody, RANKL antibody, TRANCE antibody, hRANKL2 antibody, sOdf antibody, TNF superfamily member 11 antibody, TNFSF11 antibody
    Target Type
    Biosimilar
    Background
    Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
You are here:
Support